Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: A phase II cytokine working group study

Cancer

Volumn 113, Issue 8, 2008, Pages 2139-2145

  Atkins, Michael B ^a   Sosman, Jeffrey A ^b   Agarwala, Sanjiv ^c   Logan, Theodore ^d   Clark, Joseph I ^e   Ernstoff, Marc S ^c,f   Lawson, David ^e,g   Dutcher, Janice P ^h,i   Weiss, Geoffrey ^j   Curti, Brendan ^k   Margolin, Kim A ^l  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^e LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^f NORRIS COTTON CANCER CENTER   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Our Lady of Mercy Cancer Center   (United States)

ⁱ NEW YORK MEDICAL COLLEGE   (United States)

^j University of Texas Health Science Center at San Antonio   (United States)

^k EARLE A CHILES RESEARCH INSTITUTE   (United States)

^l CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

more..

Author keywords

Brain metastases; Melanoma; Radiation therapy; Temozolomide; Thalidomide

Indexed keywords

CORTICOSTEROID; TEMOZOLOMIDE; THALIDOMIDE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; BRAIN METASTASIS; BRAIN RADIATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM METASTASIS; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEEP VEIN THROMBOSIS; DIAGNOSTIC IMAGING; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; FEMALE; HEART ARRHYTHMIA; HUMAN; LUNG EMBOLISM; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; DACARBAZINE; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; THALIDOMIDE;

EID: 55749092775     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23805     Document Type: Article

References (33)

1. Amer MH, Al-Sarraf M, Baker LH, Vaitkevicius VK. Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer. 1978;42:660-668.
2. Sampson JH, Carter JH Jr, Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg. 1998;88:11-20.
3. Atkins MB. Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin Cancer Res. 2006;12(7 pt 2):2353s-2358s.
4. Mitchell MS. Relapse in the central nervous system in melanoma patients successfully treated with biomodulators. J Clin Oncol. 1989;7:1701-1709.
5. Wronski M, Arbit E. Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients. J Neurosurg. 2000;93:9-18.
6. Konstadoulakis MM, Messaris E, Zografos G, Androulakis G, Karakousis C. Prognostic factors in malignant melanoma patients with solitary or multiple brain metastases. Is there a role for surgery? J Neurosurg Sci. 2000;44:211-218; discussion 219.
7. Mathieu D, Kondziolka D, Cooper PB, et al. Gamma knife radiosurgery in the management of malignant melanoma brain metastases. Neurosurgery. 2007;60:471-481; discussion 481-482.
8. Radbill AE, Fiveash JF, Falkenberg ET, et al. Initial treatment of melanoma brain metastases using gamma knife radiosurgery: an evaluation of efficacy and toxicity. Cancer. 2004;101:825-833.
9. Fife KM, Colman MH, Stevens GN, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol. 2004;22:1293-1300.
10. Lee SM, Thatcher N, Crowther D, Margison GP. In vivo depletion of O6-alkylguanine-DNA-alkyltransferase in lymphocytes and melanoma of patients treated with CB 10-277, a new DTIC analogue. Cancer Chemother Pharmacol. 1992;31:240-246.
11. Patel MMC, Godwin K, Balis F. Plasma and cerebrospinal fluid pharmacokinetics of temozolomide. Proc Am Soc Clin Oncol. 1995;14:1485.
12. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996.
13. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18:158-166.
14. Summers Y, Calvert H, Lee SM, Rutin G, Newell DR, Thatcher N. Effect of temozolomide on central nervous system relapse in patients with advance melanoma. Proc Am Soc Clin Oncol. 1999;18:531a.
15. Agarwala SS, Kirkwood JM, Gore M, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol. 2004;22: 2101-2107.
16. Margolin K, Atkins B, Thompson A, et al. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol. 2002;128:214-218.
17. Eisen T, Boshoff C, Mak I, et al. Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer. 2000;82:812-817.
18. Hwu WJ, Krown SE, Menell JH, et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol. 2003;21:3351-3356.
19. Kouvaris JR, Miliadou A, Kouloulias VE, et al. Phase II study of temozolomide and concomitant whole-brain radiotherapy in patients with brain metastases from solid tumors. Onkologie. 2007;30:361-366.
20. Zeitz L, Silagi S. Radiosensitivity of melanoma cells in culture: implications for radiotherapy of malignant melanoma. Br J Radiol. 1977;50:604-606.
21. Serrone L, Hersey P. The chemoresistance of human malignant melanoma: an update. Melanoma Res. 1999;9:51-58.
22. Krown SE, Niedzwiecki D, Hwu WJ, Hodgson L, Houghton AN, Haluska FG. Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). Cancer. 2006;107:1883-1890.
23. Sharma NL, Sharma VC, Mahajan VK, Shanker V, Ranjan N, Gupta M. Thalidomide: an experience in therapeutic outcome and adverse reactions. J Dermatol Treat. 2007;18:335-340.
24. Boogerd W, de Gast GC, Dalesio O. Temozolomide in advanced malignant melanoma with small brain metastases: can we withhold cranial irradiation? Cancer. 2007;109:306-312.
25. Xie TX, Huang FJ, Aldape KD, et al. Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res. 2006;66:3188-3196.
26. Schadendorf D, Hauschild A, Ugurel S, et al. Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study. Ann Oncol. 2006;17:1592-1597.
27. Conill C, Jorcano S, Domingo-Domenech J, et al. Whole brain irradiation and temozolomide based chemotherapy in melanoma brain metastases. Clin Transl Oncol. 2006;8:266-270.
28. Hofmann M, Kiecker F, Wurm R, et al. Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases. J Neurooncol. 2006;76:59-64.
29. Samlowski WE, Watson GA, Wang M, et al. Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS). Cancer. 2007;109:1855-1862.
30. Flaherty KT. Chemotherapy and targeted therapy combinations in advanced melanoma. Clin Cancer Res. 2006;12(7 pt 2):2366s-2370s.
31. Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist. 2007;12:864-872.
32. Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol. 2005;23:8968-8977.
33. Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother. 2007;56:739-745.